Best tumor response in patients with ALK+ ALCL aged <65 years with stage II to IV disease. (A-B) Best response in patients who received CHOP with or without etoposide (A) and in those with ALK⁻ ALCL, AITL, or PTCL NOS regardless of subsequent ASCT (B). Denominators include patients with ALK⁺ ALCL diagnosed in the period from 2014 to 2018 and treated with either CHOP of CHOEP (A) and patients with ALK⁻ ALCL, AITL, or PTCL NOS diagnosed in the period from 2014 to 2018 and treated with either CHOP or CHOEP (B). PD, progressive disease; PR, partial remission; SD, stable disease; UNK, unknown.